SCHEMBL24378546

SCHEMBL24378546

CCOC(=O)c1cn2c(N3CCOCC3)cc(Cl)nc2n1

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 2/20 0.45
DPP8 Q6V1X1 2/20 0.45
DPP9 Q86TI2 2/20 0.45
PIK3CA P42336 1/20 0.44
KDM4E B2RXH2 6/20 0.41
ALDH1A1 P00352 5/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
GAA P10253 1/20 0.40
HPGD P15428 2/20 0.40
ALOX15 P16050 2/20 0.40
LMNA P02545 1/20 0.40
HSD17B10 Q99714 1/20 0.40
PKM P14618 1/20 0.40
DYRK1A Q13627 1/20 0.39
AKT1 P31749 2/20 0.39
SIRT2 Q8IXJ6 1/20 0.39
SIRT1 Q96EB6 1/20 0.39
SLC2A1 P11166 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27009158 0.80 PIK3CA (0.49) PIK3CAKDM4EALDH1A1L3MBTL1HPGD
SCHEMBL13815641 0.79 PIK3CA (0.45) PIK3CAKDM4EALDH1A1L3MBTL1HPGD
SCHEMBL5439236 0.79 GAA (0.52) DPP4DPP8DPP9KDM4EALDH1A1
SCHEMBL24378550 0.79 DPP4 (0.53) DPP4DPP8DPP9KDM4EALDH1A1
SCHEMBL27009156 0.77 KDM4E (0.56) KDM4EALDH1A1HPGDLMNAHSD17B10
SCHEMBL24378544 0.74 KDM4E (0.42) PIK3CAKDM4EALDH1A1HSD17B10
SCHEMBL26079080 0.73 GAA (0.47) PIK3CAKDM4EALDH1A1L3MBTL1GAA
SCHEMBL5214322 0.73 PIK3CA (0.56) PIK3CAKDM4EALDH1A1L3MBTL1HPGD
SCHEMBL16278381 0.73 PDE10A (0.48) PIK3CAKDM4EALDH1A1L3MBTL1GAA
SCHEMBL24378575 0.72 KDM4E (0.44) PIK3CAKDM4EALDH1A1GAAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240018151-A1 NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME TME THERAPEUTICS LLC 2024-01-18 US disclosed
US-20240018151-A1 NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME TME THERAPEUTICS LLC 2024-01-18 US disclosed
WO-2022086993-A1 NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME TME THERAPEUTICS LLC (US) 2022-04-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240018151-A1 NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME PIKFYVE, PIK3CD, PIK3R5 DPP4 1014/4885DPP8 1362/4885DPP9 1198/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.